A Phase 1/2 Single Center, Randomized, Double-blind, Placebo-controlled, Left-Right Comparison Study to Evaluate the Safety and Preliminary Efficacy of a Topical Antimicrobial (NEO101) in Older Adolescents and Adults with at least Moderate Atopic Dermatitis
Latest Information Update: 16 Jul 2019
At a glance
- Drugs NEO 101 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Acronyms NEO101-CLIN-AD001
- Sponsors Neosil
- 01 Jul 2016 New trial record